UNSPSC 51372209: Dextropropoxyphene napsilate

This classification denotes an opioid receptor agonist and opioid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 38M219L1OJ. European Medicines Agency schedules Dextropropoxyphene napsilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01650MIG. Dextropropoxyphene napsilate generally arises in the molecular formula C22H29NO2.C10H8O3S.H2O. The term 'dextropropoxyphene napsilate' is a United States Adopted Name designation.

Most nations, for tariff and trade purposes, schedule dextropropoxyphene napsilate under HS 29221400. SMILES: CCC(=O)O[C@](CC1CCCCC1)(C2CCCCC2)[C@H](C)CN(C)C.C1CCC2CC(CCC2C1)S(=O)(=O)O.O.

UNSPSC 51372209 Dextropropoxyphene napsilate is a Commodity code tracking pharmaceutical procurement by state and local health agencies, though the recent opportunities under this code actually span naloxone, generic multi-source pharmaceuticals, and over-the-counter products distributed through public health systems and employee benefit programs rather than dextropropoxyphene specifically. State and local buyers under this code include county health departments, state HHS commissions, and multistate cooperative purchasing alliances that source pharmaceuticals for community health initiatives, emergency response, and employee health benefits. The work involves competitive procurement of pharmaceutical products—often in bulk quantities with quarterly or annual delivery cycles—requiring vendors to maintain cGMP and Drug Supply Chain Security Act compliance, manage relationships with authorized wholesalers, and meet stringent insurance and quality-assurance standards. Issuing bodies soliciting under the code range from individual county health departments to statewide HHS agencies to cooperative purchasing vehicles serving multiple states.

Recent activity appears across Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023 (note: posted date June 30, 2026 with a historical response deadline). The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, exploring alternative contracting models outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract award weights emphasizing price competitiveness at 75 percent. Vendors must typically maintain commercial general liability insurance of $2 million to $5 million per occurrence and comply with authorized wholesaler networks and chargebacks.